The goal of our research is to identify key immune checkpoints of gastrointestinal disorders that could be targeted for therapeutic intervention and drug development.

The ultimate aim of the Shiloh Lab is to contribute to the development of vaccines and treatments for Mycobacterium tuberculosis (Mtb).

Burstein Laboratory focuses on understanding the regulation of the inflammatory response at a molecular level, and elucidating how these events may participate in human disease.